These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3081337)

  • 1. Nutritional influence on serum ammonia in young patients receiving sodium valproate.
    Laub MC
    Epilepsia; 1986; 27(1):55-9. PubMed ID: 3081337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hyperammonemia in valproate therapy in children and adolescents].
    Laub MC
    Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood ammonia level during valproic acid therapy.
    Kugoh T; Yamamoto M; Hosokawa K
    Jpn J Psychiatry Neurol; 1986 Dec; 40(4):663-8. PubMed ID: 3110472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?
    Kondo T; Ishida M; Kaneko S; Hirano T; Otani K; Fukushima Y; Muranaka H; Koide N; Yokoyama M; Nakata S
    Epilepsia; 1992; 33(3):550-4. PubMed ID: 1350534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gait instability in valproate-treated patients: Call to measure ammonia levels.
    Kipervasser S; Elger CE; Korczyn AD; Nass RD; Quesada CM; Neufeld MY
    Acta Neurol Scand; 2017 Nov; 136(5):401-406. PubMed ID: 28436001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential ammonia decay kinetics indicates more than one concurrent etiological mechanism for symptomatic hyperammonemia caused by valproate overdose.
    Mojumder DK; De Oleo RR
    Indian J Pharmacol; 2014; 46(3):345-7. PubMed ID: 24987188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
    Hamed SA; Abdella MM
    Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction.
    Zaret BS; Beckner RR; Marini AM; Wagle W; Passarelli C
    Neurology; 1982 Feb; 32(2):206-8. PubMed ID: 6798491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluate the effects of long-term valproic acid treatment on metabolic profiles in newly diagnosed or untreated female epileptic patients: A prospective study.
    Sidhu HS; Srinivas R; Sadhotra A
    Seizure; 2017 May; 48():15-21. PubMed ID: 28365440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diet- and valproate-induced transient hyperammonemia: effect of L-carnitine.
    Gidal BE; Inglese CM; Meyer JF; Pitterle ME; Antonopolous J; Rust RS
    Pediatr Neurol; 1997 May; 16(4):301-5. PubMed ID: 9258962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors of hyperammonemia in epilepsy patients with valproic acid therapy.
    Kwack DW; Kim DW
    Clin Neurol Neurosurg; 2023 Oct; 233():107962. PubMed ID: 37717359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperammonemia following intravenous valproate loading.
    DeWolfe JL; Knowlton RC; Beasley MT; Cofield S; Faught E; Limdi NA
    Epilepsy Res; 2009 Jul; 85(1):65-71. PubMed ID: 19299111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum carnitine during valproic acid therapy.
    Laub MC; Paetzke-Brunner I; Jaeger G
    Epilepsia; 1986; 27(5):559-62. PubMed ID: 3093213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
    Yamada H; Shishido T; Mukai T; Araki M; Naka H; Tokinobu H
    Rinsho Shinkeigaku; 2019 May; 59(5):258-263. PubMed ID: 31061301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs.
    Verrotti A; Greco R; Morgese G; Chiarelli F
    Int J Clin Lab Res; 1999; 29(1):36-40. PubMed ID: 10356662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of associated antiepileptic treatment on valproate-induced hyperammonemia.
    Zaccara G; Paganini M; Campostrini R; Moroni F; Valenza T; Messori A; Bartelli M; Arnetoli G; Zappoli R
    Ther Drug Monit; 1985; 7(2):185-90. PubMed ID: 3927530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy.
    Stephen LJ; Kwan P; Shapiro D; Dominiczak M; Brodie MJ
    Epilepsia; 2001 Aug; 42(8):1002-6. PubMed ID: 11554885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of relationship between sodium valproate-induced adverse effects and the plasma concentration of its metabolite 2-propylpenten-4-oic acid.
    Paganini M; Zaccara G; Moroni F; Campostrini R; Bendoni L; Arnetoli G; Zappoli R
    Eur J Clin Pharmacol; 1987; 32(2):219-22. PubMed ID: 3108013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of carnitine supplementation in valproate-induced hyperammonaemia.
    Böhles H; Sewell AC; Wenzel D
    Acta Paediatr; 1996 Apr; 85(4):446-9. PubMed ID: 8740302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures.
    Gal P; Oles KS; Gilman JT; Weaver R
    Neurology; 1988 Mar; 38(3):467-71. PubMed ID: 3126410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.